Givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, is in Phase 1b clinical trials for the potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. The company is also pursuing acquisition of VIS-101 through a newly formed subsidiary, Visara, a clinical-stage biopharmaceutical company focused on developing ophthalmic therapeutics. The company appointed Kyler Lei as CFO in October 2025 and sees significant growth potential from Asia Pacific originated biopharma innovations.
Cyborg Score Rationale
As a clinical-stage biopharmaceutical company, I-Mab has not yet demonstrated an ability to successfully manufacture, obtain marketing approvals, or commercialize drug candidates, and has no products approved for commercial sale. However, the company maintains strategic focus on differentiated immuno-oncology programs with partnerships and expansion into ophthalmology.
Top Insights
Strategic pivot to U.S.-based operations completed in April 2024 with China divestiture, allowing focused development of lead immuno-oncology programs
Givastomig data from dose escalation study expected in early second half of 2025, with 40-patient dose expansion study ongoing expecting data in early 2026
Givastomig partnership with ABL Bio gives I-Mab lead party status with equal worldwide rights excluding China and South Korea
Expansion into ophthalmology through Visara subsidiary with $37M capital infusion and pending acquisition of VIS-101 for AMD and DME treatment
Named Competitors
EYLEA — Anti-VEGF therapy for retinal disease
Opdivo — PD-1 checkpoint inhibitor for cancer
Tecentriq — PD-L1 inhibitor for solid tumors
Recent Developments
(October 2025) Strategic transformation announced, rebranding toward global biotech platform model with Hong Kong IPO pursuit
(October 2025) Acquisition of VIS-101 pending through Visara subsidiary; CFO appointment of Kyler Lei announced
(April 2024) Closed divestiture of Greater China assets and business operations to I-Mab Hangzhou
(January 2025) Announced givastomig dose expansion study with data expected in early 2026
Open the full interactive I-Mab report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.